Tumor News and Research

RSS

Cancer cells feed on sugar-free diet

Cancer cells have been long known to have a “sweet tooth,” using vast amounts of glucose for energy and for building blocks for cell replication.

10 Jan 2012

MAL3-101 appears to have potent anti-tumor effects on multiple myeloma

A new study from SUNY Downstate Medical Center in Brooklyn, New York, shows that MAL3-101, a recently developed inhibitor of the heat shock protein 70 (Hsp70), appears to have potent anti-tumor effects on multiple myeloma, a bone marrow cancer.

10 Jan 2012

QIAGEN's therascreen EGFR Mutation Detection Kit receives Japanese regulatory approval

QIAGEN today announced the regulatory approval of its therascreen EGFR Mutation Detection Kit RGQ in Japan. EGFR, the epidermal growth factor receptor, has been shown to play an important role in certain cancers and is the target of many new anticancer drugs.

From QIAGEN Manchester Limited 10 Jan 2012

Personalized therapies may improve survival and QoL of patients with glioblastoma

Personalized prognostic tools and gene-based therapies may improve the survival and quality of life of patients suffering from glioblastoma, an aggressive and deadly form of brain cancer, reports a new University of Illinois study funded by the NIH National Cancer Institute.

10 Jan 2012

HDC, NeoGenomics sign worldwide licensing agreement to develop LDT

Health Discovery Corporation, a molecular diagnostics leader in the use of patent protected advanced mathematical techniques for personalized medicine, has entered into an exclusive worldwide licensing agreement with NeoGenomics, Inc. for laboratory developed tests in the Field of hematopoietic and solid tumor cancers excluding breast cancer, which was previously licensed to Quest Diagnostics and Smart Personalized Medicine and excluding cancer of the retina which was previously committed to Retinalyze, LLC.

9 Jan 2012

TRON uses Ingenuity Variant Analysis to identify cancer driver variants

Ingenuity Systems, a leading provider of information and analysis solutions for life science researchers, today announced that TRON has used Ingenuity Variant Analysis to identify cancer driver variants that inform the development of an experimental individualized RNA-based therapeutic.

9 Jan 2012

Pfizer, SFJ to conduct axitinib Phase 3 trial in renal cell carcinoma

SFJ Pharma Ltd. II announced today that it has entered into a collaborative development agreement with Pfizer Inc. to conduct a Phase 3 clinical trial in Asia of Pfizer's investigational agent axitinib for the adjuvant treatment of patients at high risk of recurrent renal cell carcinoma (RCC) following nephrectomy.

9 Jan 2012

Scientists identify key tumorigenic pathways in never-smoker lung adenocarcinoma patients

Researchers at the Translational Genomics Research Institute (TGen) have begun to identify mutations and cellular pathway changes that lead to lung cancer in never-smokers - a first step in developing potential therapeutic targets.

9 Jan 2012

Study shows high consistency of malignancy-risk gene signature on both breast cancer and NSCLC

A malignancy-risk gene signature developed for breast cancer has been found to have predictive and prognostic value for patients with early stage non-small cell lung cancer. The advancement was made by researchers at Moffitt Cancer Center in Tampa, Fla., who published their study results in a recent issue of the Journal of the National Cancer Institute.

7 Jan 2012

FDG-PET safe and accurate in detecting dementia, Alzheimer's

In a new review of imaging studies spanning more than ten years, scientists find that a method of positron emission tomography (PET) safely and accurately detects dementia, including the most common and devastating form among the elderly, Alzheimer's disease.

7 Jan 2012

TrovaGene enters definitive agreement to acquire MultiGEN

TrovaGene, Inc., a developer of trans-renal molecular diagnostics, today announced that it has entered into a definitive agreement to acquire MultiGEN Diagnostics, Inc.'s clinical laboratory assets in exchange for the issuance of 750,000 shares of common stock of TrovaGene, with an additional earn-out of up to $3.7 million in cash and common stock, subject to the achievement of specific sales and earnings targets.

6 Jan 2012

SonoPhoto Dynamic Therapy shows promise against squamous cell carcinoma

George Miller developed an ulcer on his bottom lip that began to bleed. His doctor sent cell scrapings to a pathologist, and diagnosed Miller with squamous cell carcinoma (SCC). According to TMD Limited, a medical tourism company, squamous cell carcinoma is the 2nd most common cancer in humans and other animals.

6 Jan 2012

Researchers discover that flatworm lacks centrosome

A tiny, freshwater flatworm found in ponds and rivers around the world that has long intrigued scientists for its remarkable ability to regenerate has now added a new wrinkle to biology.

6 Jan 2012

Fibroblasts play an apparent role in melanoma tumor growth

Fibroblasts, cells that play a role in the structural framework of tissues, play an apparent role in melanoma tumor growth. Fibroblasts also contribute to melanoma drug resistance and may also facilitate the "flare" response when a tumor's metabolism is enhanced following a patient being removed from a targeted therapy, said researchers at Moffitt Cancer Center in Tampa, Fla.

6 Jan 2012

Wake Forest Baptist participates in novel brain tumor vaccine clinical trial

A national clinical trial testing the efficacy of a novel brain tumor vaccine has begun at Wake Forest Baptist Medical Center, the only facility in the Southeast to participate.

6 Jan 2012

UCSD surgeons perform west coast's first ex-vivo liver resection

A team led by Alan Hemming, MD, transplant surgeon at UC San Diego Health System, has successfully performed the west coast's first ex-vivo liver resection, a radical procedure to completely remove and reconstruct a diseased liver and re-implant it without any tumors. The procedure saved the life of a 27-year old mother whose liver had been invaded by a painful tumor that crushed the organ and entangled its blood supply.

6 Jan 2012

New anti-tumor compounds show promise for hard-to-treat cancers

New anti-tumor compounds produced by Dr. Aleem Gangjee, Distinguished Professor of Medicinal Pharmacy at Duquesne University's Mylan School of Pharmacy, show such promise for fighting hard-to-treat tumors that the National Institutes of Health (NIH) has placed them on its fast track for development.

6 Jan 2012

Lithocholic acid can kill several types of cancer cells

Lithocholic acid (LCA), naturally produced in the liver during digestion, has been seriously underestimated. A study published in the journal Oncotarget shows that LCA can kill several types of cancer cells, such as those found in some brain tumors and breast cancer.

5 Jan 2012

$Viamet commences VT-464 Phase 1/2 trial in castration-refractory prostate cancer$

Viamet commences VT-464 Phase 1/2 trial in castration-refractory prostate cancer

Viamet Pharmaceuticals, Inc., announced today that dosing has begun in a Phase 1/2 clinical trial of VT-464, an oral, potent and lyase-selective CYP17 inhibitor for the treatment of castration-refractory prostate cancer.

4 Jan 2012

PEDF may suppress brain from tumor-induced damage, metastasis

Scientists are one step closer to repairing the damage caused by brain metastasis, a major challenge in cancer treatment, according to data published in Cancer Research, a journal of the American Association for Cancer Research.

4 Jan 2012